Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PD-L1 overexpression
i
Other names:
PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
29126
Related biomarkers:
Expression
Mutation
CNA
Others
‹
PD-L1 elevation (15)
TMB-H + PD-L1 expression (15)
EGFR mutation + PD-L1 overexpression (8)
TMB-H + PD-L1 overexpression (7)
EGFR exon 19 deletion + PD-L1 overexpression (5)
EGFR mutation + PD-L1 expression (5)
KRAS G12C + PD-L1 overexpression (4)
KRAS mutation + PD-L1 expression (4)
MSI-H/dMMR + PD-L1 expression (4)
PD-L1 expression + EGFR mutation (4)
CD74-ROS1 F2004L + PD-L1 expression (3)
EGFR wild-type + ALK wild-type + PD-L1 expression (3)
MSI-H/dMMR + TMB-H + PD-L1 negative (3)
PD-L1 expression + TMB-H (3)
PD-L1 overexpression + KRAS mutation (3)
ALK rearrangement + PD-L1 overepxression (2)
BRAF V600E + PD-L1 expression (2)
BRAF V600E + PD-L1 expression (2)
EGFR L858R + PD-L1 overexpression (2)
EGFR exon 19 deletion + PD-L1 expression (2)
HER-2 amplification + PD-L1 expression (2)
KRAS G12C + PD-L1 underexpression (2)
KRAS mutation + PD-L1 negative (2)
MSI-H/dMMR + TMB-H + PD-L1 overexpression (2)
PD-1-L + PD-L1 elevation (2)
PD-L1 expression + NRAS Q61R + BRAF D594N (2)
PD-L1 expression + TMB-H + FANCA deletion (2)
PD-L1 overexpression + BRAF V600E (2)
PD-L1 overexpression + EGFR mutation (2)
PD-L1 overexpression + FGFR3 amplification (2)
PD-L1 overexpression + MET exon 14 mutation (2)
RAD51B promoter methylation + PD-L1 expression (2)
TMB-H + PD-L1 negative (2)
TMB-H + PD-L1 underexpression (2)
TMB-L + PD-L1 expression (2)
ALK wild-type + NT5E overexpression + PD-L1 expression (1)
ALK-EML4_V3a + PD-L1 overexpression (1)
ALK-EML4_V3b + PD-L1 overexpression (1)
BAP1 R300Gfs*6 + PD-L1 expression (1)
BAP1 deletion + TMB-L + PD-L1 expression (1)
BRAF E501Q + PD-L1 negative (1)
BRAF V600 + LDH elevation + PD-L1 negative (1)
BRAF mutation + PD-L1 overexpression (1)
BRCA1 mutation + PD-L1 expression (1)
CDKN2A mutation + PD-L1 overexpression (1)
Chr del(9p) + PD-L1 overexpression (1)
DDR + PD-L1 expression (1)
EGFR G719A + EGFR S768I + PD-L1 overexpression (1)
EGFR G719A + PD-L1 overexpression (1)
EGFR L747P + PD-L1 overexpression (1)
EGFR L858R + PD-L1 expression (1)
EGFR L858R + PD-L1 underexpression (1)
EGFR P719A + PD-L1 overexpression (1)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)
EGFR exon 19 deletion + EGFR T790M + PD-L1 expression (1)
EGFR exon 19 deletion + PD-L1 underexpression (1)
EGFR exon 20 insertion + PD-L1 overexpression (1)
EGFR fusion + PD-L1 overexpression (1)
EGFR mutation + PD-L1 elevation (1)
EGFR mutation + PD-L1 expression + TP53 mutation (1)
EGFR mutation + PD-L1 negative (1)
EGFR negative + ALK negative + PD-L1 expression (1)
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)
FGFR mutation + PD-L1 expression (1)
HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)
HLA-A*02 + PD-L1 expression (1)
HLA-A*02:01 + PD-L1 expression (1)
HRAS Q61R + TP53 P278S + PD-L1 overexpression (1)
KEAP1 mutation + TMB-H + PD-L1 overexpression (1)
KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression (1)
KRAS G12C + PD-L1 expression (1)
KRAS G12C + PD-L1 underexpression + STK11 mutation (1)
KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)
KRAS mutation + PD-L1 underexpression (1)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)
LDHA-L + PD-L1 expression (1)
LDHB-L + PD-L1 expression (1)
MET exon 14 mutation + MET amplification + PD-L1 overexpression (1)
MGAM mutation + PD-L1 overexpression (1)
PAPPA2 mutation + PD-L1 expression (1)
PD-L1 amplification + CD3D overexpression (1)
PD-L1 amplification + HLA-DRA overexpression (1)
PD-L1 amplification + LAG3 overexpression (1)
PD-L1 amplification + PD-L2 amplification + TMB-H (1)
PD-L1 deletion + STK11 mutation (1)
PD-L1 elevation + CXCL10 elevation + TNFA elevation (1)
PD-L1 expression + BRAF negative (1)
PD-L1 expression + JAK2 mutation (1)
PD-L1 expression + KMT2D mutation (1)
PD-L1 expression + MSI-H/dMMR (1)
PD-L1 expression + MSI-L/dMMR (1)
PD-L1 expression + PIK3CA mutation (1)
PD-L1 expression + STK11 mutation (1)
PD-L1 expression + STK11 mutation + JAK2 mutation (1)
PD-L1 expression + T-cell gene signature (1)
PD-L1 negative + KRAS G12C (1)
PD-L1 negative + TMB-L (1)
PD-L1 negative + TMB-L + STING overexpression (1)
PD-L1 overexpression + HER-2 exon 20 insertion (1)
PD-L1 overexpression + KRAS G12C + TP53 mutation (1)
PD-L1 overexpression + RET-CCDC6 fusion (1)
PD-L1 overexpression + RET-KIF5B fusion (1)
PD-L1 overexpression + RET-KIF5B fusion + TP53 mutation + AR mutation + RET rearrangement (1)
PD-L1 overexpression + TMB-H (1)
PD-L1 overexpression + TMB-H + ARID1A F2141fs*59 (1)
PD-L1 overexpression + TMB-L (1)
PD-L1 underexpression + EGFR mutation (1)
PD-L1-L (1)
PIK3CA R88Q + PD-L1 expression (1)
POLE mutation + PD-L1 negative + TMB-H (1)
RB1 mutation + PD-L1 expression (1)
RET amplification + TMB-H + PD-L1 expression (1)
ROS1 rearrangement + PD-L1 overexpression (1)
RYR1 mutation + PD-L1 overexpression (1)
SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression (1)
SQSTM1-NTRK1 + PIK3CA E545K + TP53 L145R + PD-L1 overexpression (1)
STK11 mutation + TMB-H + PD-L1 overexpression (1)
TERT positive + PD-L1 expression (1)
TMB-H + PD-L1 expression + MSI-L/dMMR (1)
TMB-H + RB1 mutation + PD-L1 underexpression (1)
TMB-L + PD-L1 underexpression (1)
TP53 mutation + MET amplification + PD-L1 overexpression (1)
TP53 mutation + PD-L1 expression (1)
TP53 mutation + PD-L1 negative (1)
TP53 mutation + TMB-H + PD-L1 overexpression (1)
TTF1 expression + NAPSA expression + PD-L1 expression + TMB-H (1)
ARID1A mutation + PD-L1 expression (0)
DDX3X mutation + PD-L1 overexpression (0)
LDHA-H + PD-L1 negative (0)
LDHB-H + PD-L1 negative (0)
NOTCH4 mutation + PD-L1 expression + TMB-H (0)
PD-L1 overexpression + BRAF mutation (0)
PD-L1 underexpression + ALK wild-type (0)
PD-L1 underexpression + EGFR wild-type (0)
PD-L1-H (0)
STAT3 mutation + PD-L1 overexpression (0)
PD-L1 elevation (15)
TMB-H + PD-L1 expression (15)
EGFR mutation + PD-L1 overexpression (8)
TMB-H + PD-L1 overexpression (7)
EGFR exon 19 deletion + PD-L1 overexpression (5)
EGFR mutation + PD-L1 expression (5)
KRAS G12C + PD-L1 overexpression (4)
KRAS mutation + PD-L1 expression (4)
MSI-H/dMMR + PD-L1 expression (4)
PD-L1 expression + EGFR mutation (4)
CD74-ROS1 F2004L + PD-L1 expression (3)
EGFR wild-type + ALK wild-type + PD-L1 expression (3)
MSI-H/dMMR + TMB-H + PD-L1 negative (3)
PD-L1 expression + TMB-H (3)
PD-L1 overexpression + KRAS mutation (3)
ALK rearrangement + PD-L1 overepxression (2)
BRAF V600E + PD-L1 expression (2)
BRAF V600E + PD-L1 expression (2)
EGFR L858R + PD-L1 overexpression (2)
EGFR exon 19 deletion + PD-L1 expression (2)
HER-2 amplification + PD-L1 expression (2)
KRAS G12C + PD-L1 underexpression (2)
KRAS mutation + PD-L1 negative (2)
MSI-H/dMMR + TMB-H + PD-L1 overexpression (2)
PD-1-L + PD-L1 elevation (2)
PD-L1 expression + NRAS Q61R + BRAF D594N (2)
PD-L1 expression + TMB-H + FANCA deletion (2)
PD-L1 overexpression + BRAF V600E (2)
PD-L1 overexpression + EGFR mutation (2)
PD-L1 overexpression + FGFR3 amplification (2)
PD-L1 overexpression + MET exon 14 mutation (2)
RAD51B promoter methylation + PD-L1 expression (2)
TMB-H + PD-L1 negative (2)
TMB-H + PD-L1 underexpression (2)
TMB-L + PD-L1 expression (2)
ALK wild-type + NT5E overexpression + PD-L1 expression (1)
ALK-EML4_V3a + PD-L1 overexpression (1)
ALK-EML4_V3b + PD-L1 overexpression (1)
BAP1 R300Gfs*6 + PD-L1 expression (1)
BAP1 deletion + TMB-L + PD-L1 expression (1)
BRAF E501Q + PD-L1 negative (1)
BRAF V600 + LDH elevation + PD-L1 negative (1)
BRAF mutation + PD-L1 overexpression (1)
BRCA1 mutation + PD-L1 expression (1)
CDKN2A mutation + PD-L1 overexpression (1)
Chr del(9p) + PD-L1 overexpression (1)
DDR + PD-L1 expression (1)
EGFR G719A + EGFR S768I + PD-L1 overexpression (1)
EGFR G719A + PD-L1 overexpression (1)
EGFR L747P + PD-L1 overexpression (1)
EGFR L858R + PD-L1 expression (1)
EGFR L858R + PD-L1 underexpression (1)
EGFR P719A + PD-L1 overexpression (1)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)
EGFR exon 19 deletion + EGFR T790M + PD-L1 expression (1)
EGFR exon 19 deletion + PD-L1 underexpression (1)
EGFR exon 20 insertion + PD-L1 overexpression (1)
EGFR fusion + PD-L1 overexpression (1)
EGFR mutation + PD-L1 elevation (1)
EGFR mutation + PD-L1 expression + TP53 mutation (1)
EGFR mutation + PD-L1 negative (1)
EGFR negative + ALK negative + PD-L1 expression (1)
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)
FGFR mutation + PD-L1 expression (1)
HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)
HLA-A*02 + PD-L1 expression (1)
HLA-A*02:01 + PD-L1 expression (1)
HRAS Q61R + TP53 P278S + PD-L1 overexpression (1)
KEAP1 mutation + TMB-H + PD-L1 overexpression (1)
KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression (1)
KRAS G12C + PD-L1 expression (1)
KRAS G12C + PD-L1 underexpression + STK11 mutation (1)
KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)
KRAS mutation + PD-L1 underexpression (1)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)
LDHA-L + PD-L1 expression (1)
LDHB-L + PD-L1 expression (1)
MET exon 14 mutation + MET amplification + PD-L1 overexpression (1)
MGAM mutation + PD-L1 overexpression (1)
PAPPA2 mutation + PD-L1 expression (1)
PD-L1 amplification + CD3D overexpression (1)
PD-L1 amplification + HLA-DRA overexpression (1)
PD-L1 amplification + LAG3 overexpression (1)
PD-L1 amplification + PD-L2 amplification + TMB-H (1)
PD-L1 deletion + STK11 mutation (1)
PD-L1 elevation + CXCL10 elevation + TNFA elevation (1)
PD-L1 expression + BRAF negative (1)
PD-L1 expression + JAK2 mutation (1)
PD-L1 expression + KMT2D mutation (1)
PD-L1 expression + MSI-H/dMMR (1)
PD-L1 expression + MSI-L/dMMR (1)
PD-L1 expression + PIK3CA mutation (1)
PD-L1 expression + STK11 mutation (1)
PD-L1 expression + STK11 mutation + JAK2 mutation (1)
PD-L1 expression + T-cell gene signature (1)
PD-L1 negative + KRAS G12C (1)
PD-L1 negative + TMB-L (1)
PD-L1 negative + TMB-L + STING overexpression (1)
PD-L1 overexpression + HER-2 exon 20 insertion (1)
PD-L1 overexpression + KRAS G12C + TP53 mutation (1)
PD-L1 overexpression + RET-CCDC6 fusion (1)
PD-L1 overexpression + RET-KIF5B fusion (1)
PD-L1 overexpression + RET-KIF5B fusion + TP53 mutation + AR mutation + RET rearrangement (1)
PD-L1 overexpression + TMB-H (1)
PD-L1 overexpression + TMB-H + ARID1A F2141fs*59 (1)
PD-L1 overexpression + TMB-L (1)
PD-L1 underexpression + EGFR mutation (1)
PD-L1-L (1)
PIK3CA R88Q + PD-L1 expression (1)
POLE mutation + PD-L1 negative + TMB-H (1)
RB1 mutation + PD-L1 expression (1)
RET amplification + TMB-H + PD-L1 expression (1)
ROS1 rearrangement + PD-L1 overexpression (1)
RYR1 mutation + PD-L1 overexpression (1)
SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression (1)
SQSTM1-NTRK1 + PIK3CA E545K + TP53 L145R + PD-L1 overexpression (1)
STK11 mutation + TMB-H + PD-L1 overexpression (1)
TERT positive + PD-L1 expression (1)
TMB-H + PD-L1 expression + MSI-L/dMMR (1)
TMB-H + RB1 mutation + PD-L1 underexpression (1)
TMB-L + PD-L1 underexpression (1)
TP53 mutation + MET amplification + PD-L1 overexpression (1)
TP53 mutation + PD-L1 expression (1)
TP53 mutation + PD-L1 negative (1)
TP53 mutation + TMB-H + PD-L1 overexpression (1)
TTF1 expression + NAPSA expression + PD-L1 expression + TMB-H (1)
ARID1A mutation + PD-L1 expression (0)
DDX3X mutation + PD-L1 overexpression (0)
LDHA-H + PD-L1 negative (0)
LDHB-H + PD-L1 negative (0)
NOTCH4 mutation + PD-L1 expression + TMB-H (0)
PD-L1 overexpression + BRAF mutation (0)
PD-L1 underexpression + ALK wild-type (0)
PD-L1 underexpression + EGFR wild-type (0)
PD-L1-H (0)
STAT3 mutation + PD-L1 overexpression (0)
›
Related tests:
PD-L1 IHC 22C3 pharmDx (55)
VENTANA PD-L1 (SP263) Assay (31)
PD-L1 IHC 22C3 pharmDx (55)
VENTANA PD-L1 (SP263) Assay (31)
Associations
(181)
News
Trials
Search handles
@AndresFCardonaZ
@BiagioMd
@DocCatenacci
@GautschiOliver
@JackWestMD
@Jbauml
@StephenVLiu
@VivekSubbiah
@cassilandense
@gabe_a_brooks
@jesusanampa
@n8pennell
@neerajaiims
@pashtoonkasi
Search handles
@AndresFCardonaZ
@BiagioMd
@DocCatenacci
@GautschiOliver
@JackWestMD
@Jbauml
@StephenVLiu
@VivekSubbiah
@cassilandense
@gabe_a_brooks
@jesusanampa
@n8pennell
@neerajaiims
@pashtoonkasi
Filter by
Latest
10ms
🚨Very high PD-L1 expression (>90%), high TMB, and increased CD8+PD1+ T cells density associate w/ prolonged benefit from CRT ➡️durvalumab in stage III #NSCLC. Out in @NatureComms our multi-center analysis led by🌟 @alessi_joao. #biomarkers can help⬆️outcomes. @OncoAlert #LCSM (@BiagioRicciutMD)
10 months ago
Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • TMB-H • PD-L1 overexpression
|
Imfinzi (durvalumab)
1year
5/8 In examining clinical outcomes to PD-(L)1 based therapies, there was no difference between patients with ATM mutant and ATM wild-type NSCLC, despite increased TMB/PD-L1 expression (though higher rate of KRAS/STK11 co-mutations) in the ATM mutant subset. (@BiagioMd)
1 year ago
Clinical • Clinical data • IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ATM (ATM serine/threonine kinase) • STK11 (Serine/threonine kinase 11)
|
PD-L1 expression • KRAS mutation • PD-L1 overexpression • ATM mutation • STK11 mutation • ATM expression • KRAS expression
1year
6/8 By contrast, concurrent ATM/TP53 mutations were associated with increased TMB, high PD-L1 expression, and improved ORR and PFS with PD-(L)1 blockade in patients NSCLC. (@BiagioMd)
1 year ago
Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • ATM (ATM serine/threonine kinase)
|
PD-L1 expression • TP53 mutation • PD-L1 overexpression
over1year
Congratulations! Very high PDL1 expression in 1/3 of RET-NSCLC can mislead clinicians to use IO upfront therapy, which is ineffective and therefore contraindicated here (@GautschiOliver)
over 1 year ago
Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
over1year
💡one fun fact that I recently learnt. The reason why PD-L1 expression is very high in #EBV associated gastric cancer is that the virus 🦠 simplistically grows through the PD-L1 highway 🛣. So technically your non-MSI that has a high ⬆️CPS gastric cancer would be your EBV➕. (@pashtoonkasi)
over 1 year ago
IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
over1year
What is your threshold of high PD-L1 expression for prescribing single-agent immunotherapy in 1L advanced NSCLC? Review the data from a trial that enrolled advanced NSCLC patients with PD-L1 ≥50% here: https://t.co/wEx0TbqbZq #SponsoredByRegeneron (@edgardo_ny)
over 1 year ago
Clinical • Review • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
over1year
Prevalence of PD-L1 high expression in advanced #UrothelialCarcinoma: results from the #PREVAIL prospective cohort study. Presentation by @PGrivasMDPhD @UW. #ESMO22 written coverage by @WallisCJD @UofT on UroToday > https://t.co/TPRPJsffBD @myESMO (@urotoday)
over 1 year ago
Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
almost2years
Capmatinib Plus Pembrolizumab Does Not Provide Clinical Benefit in MET Unselected, PD-L1-high Expressing NSCLC @TonyMok9 @ASCO #ASCO22 #lcsm https://t.co/AAYycXEh1y (@OncLive)
almost 2 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression • PD-L1-H
|
Keytruda (pembrolizumab) • Tabrecta (capmatinib)
almost2years
During a live virtual event, Ravi Salgia, MD, PhD, discussed the use of immune checkpoint inhibitor monotherapy for a patient with non–small cell lung cancer with very high PD-L1 expression with participants. #nsclc #lcsm @DrRaviSalgia @cityofhope https://t.co/SfAmDTLkVr (@TargetedOnc)
almost 2 years ago
Clinical • Checkpoint inhibition • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
2years
Report @LungCaJournal that high PDL1 expression in #ALK NSCLC associated with worse outcomes. #PDL1 high (23% of pts) had shorter PFS and shorter OS. Surrogate for specific variants or co-mutations? This does not equate to immunotherapy efficacy though! https://t.co/mlHbOmSChK (@StephenVLiu)
2 years ago
Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • PD-L1 overexpression
2years
Atezolizumab shows little heterogeneity in efficacy in high PD-L1 expressers with stage II–IIIA NSCLC #ELCC22 #LCSM https://t.co/vlv5oYCHtJ (@n8pennell)
2 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
|
Tecentriq (atezolizumab)
2years
#TTLC22 In P09, Dr. Yunan Nie reports high PDL1 expression in patients with #ALK NSCLC linked to worse prognosis on ALK TKI. No difference in RR but PFS much shorter in PDL1 high (14m) vs PDL1 low/neg (54m). Prognostic power, but biologically, how is PDL1 linked to resistance? (@StephenVLiu)
2 years ago
Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression • PD-1-L
2years
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study) | Journal for ImmunoTherapy of Cancer https://t.co/iUceXrvjnB (@VivekSubbiah)
2 years ago
IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
|
Avastin (bevacizumab) • Tecentriq (atezolizumab)
over2years
#LungCancer - Most Viewed Reviews, 2021 ⭐ #2: A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With #NSCLC and High PD-L1 Expression 👨⚕️👩⚕️@DrRoyHerbstYale) et al. Read here 👉 https://t.co/d9mp5vCiUK @YaleCancer #LCsm (@FrontOncology)
over 2 years ago
Retrospective data • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
almost3years
Enjoyed the stimulating discussion with @PGrivasMDPhD @tompowles1 @sonpavde : most important messages 👉tumor PD-L1 expression is highly "unreliable" & platinum chemo (followed by avelumab maintenance) remains the most favored treatment for most pts with advanced #bladdercancer (@neerajaiims)
almost 3 years ago
Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
|
Bavencio (avelumab)
almost3years
MORE w/ #ASCO21 abstract released today: Landscape of KRASG12C, associated genomic alterations, and interrelation with immuno-oncology (IO) biomarkers. Relationship to high TMB and PD-L1 overexpression. #Colorectal #CRCSM @agrothey @JeanneTie https://t.co/9D9lPl59AJ (@fireflyann)
almost 3 years ago
IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden)
|
TMB-H • PD-L1 overexpression • KRAS G12C • KRAS G12 • TMB-H + PD-L1 overexpression
almost3years
Is PD-L1 expression higher in HER-2 positive gastric cancer? Or is there another explanation for “synergism”? Exciting for sure - will be intrigued to learn more. (@gabe_a_brooks)
almost 3 years ago
IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • HER-2 positive • PD-L1 overexpression • HER-2 expression
3years
The Onco-Onion News in Brief: BMS, Investigators ‘thrilled’ at improving OS in all gastric cancer patients with immunotherapy Today the FDA approved nivolumab for first line therapy with chemotherapy. “While we are pleased about the high PDL1 expressers, we are most (@DocCatenacci)
3 years ago
Clinical • FDA event
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
|
Opdivo (nivolumab)
3years
Great to have an FDA-approved option for high PDL1 expressing tumors of the esophagus and GEJ with chemo+pembro in first line setting - where it should be used. @OncoAlert (@DocCatenacci)
3 years ago
Clinical • FDA event
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
|
Keytruda (pembrolizumab)
3years
5/5 Oncogene addicted NSCLC are characterised by low TMB + less inflammatory tumour microenvironment+poor tumour-infiltrating lymphocytes. PD-L1 can be overexpressed without having any clinical significance @OncoAlert @Alfdoc2 https://t.co/BSh1H3THzW (@VivekSubbiah)
3 years ago
Clinical
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 overexpression • TMB-L
3years
As PI in the EMPOWER Lung 1 trial, I’m happy with FDA Approval to Cemiplimab-rwlc for Patients With NSCLC and High PD-L1 Expression - The ASCO Post https://t.co/UGOqGi8kne @ASCO @JGO_ASCO @GlopesMd @FroitbergM @EricTopol @GBOT_Alerta @mab_sp125 @NicoleRossiOnco @vencerocancer (@cassilandense)
3 years ago
Clinical • FDA event • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
|
Libtayo (cemiplimab-rwlc)
3years
KRAS G12C (vs other KRAS mutations) were more likely to have lymphovascular invasion and had a higher #TMB (with more STK11 and NF1 mutations). KRAS also more likely to have high PDL1 expression (37% in KRAS G12C, 35% in KRAS other, 25% in KRAS WT). #LCSM @kRasKickers (@StephenVLiu)
3 years ago
IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • NF1 (Neurofibromin 1)
|
PD-L1 expression • KRAS mutation • PD-L1 overexpression • KRAS G12C • STK11 mutation • NF1 mutation • KRAS G12 • KRAS expression
over3years
Your patient w/adv non-squam NSCLC, no driver mut'n, & high PD-L1 express'n has had a good PR, still residual primary tumor, several smaller but still enlarged LNs, & a few met foci in bones, more sclerotic now. What do you recommend after 2 yrs if no restriction from payer? (@JackWestMD)
over 3 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
over3years
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy https://t.co/Sv8PN6Ykzz (@AndresFCardonaZ)
over 3 years ago
Clinical • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
|
Keytruda (pembrolizumab)
over3years
KEYNOTE-062 trial in loc adv gastric/GE jxn cancer shows 1st line pembrolizumab is non-inf to chemo w/greater tx effect in pts w/MSI-H or high PD-L1 expression (CPS >10) & no meaningful benefit of pembro+chemo observed https://t.co/8NQCYRfefG @KoheiShitara #VisualAbstract #GICSM (@JAMAOnc)
over 3 years ago
Clinical • MSi-H Biomarker • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR • PD-L1 overexpression
|
Keytruda (pembrolizumab)
over3years
IMpower110: Atezolizumab monotherapy resulted in longer overall survival (20.2 vs. 13.1 months) than platinum-based combination chemotherapy among patients with previously untreated metastatic NSCLC with high PD-L1 expression @OncoAlert @DrRoyHerbstYale https://t.co/RTXW194P2I (@jesusanampa)
over 3 years ago
Clinical • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
|
Tecentriq (atezolizumab)
over3years
The presence of MSI-H by IHC must be validated by NGS, it is a rare and almost exclusive condition for carcinoids and SCLC. The NSCLC BRAF+ that respond to IO are usually non-V600E, the V600E tend to have equivocal H-PDL1 due to IFN overexpression. I used BRAF targeted therapy 1L (@AndresFCardonaZ)
over 3 years ago
MSi-H Biomarker • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression
over3years
KEYNOTE-062 trial in loc adv gastric/GE jxn cancer shows 1st line pembrolizumab is non-inf to chemo w greater tx effect in pts w/MSI-H or high PD-L1 expression (CPS >10) & no meaningful benefit of pembro+chemo observed https://t.co/q4pnfUU8Fu @KoheiShitara #GICSM #VisualAbstract (@JAMAOnc)
over 3 years ago
Clinical • MSi-H Biomarker • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR • PD-L1 overexpression
|
Keytruda (pembrolizumab)
almost4years
The updated ORR and PFS are presented here, noting an increase in ORR. Difference seems amplify with PD-L1 overexpression. Surprising - why should PD-L1 lead to TIGIT working better. I would note that the ORR to atezolizumab alone in this group seems low. #ASCO20 #LCSM (@Jbauml)
almost 4 years ago
PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 overexpression • PD-L1 amplification
|
Tecentriq (atezolizumab)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login